Pathogenesis

Researchers Comment on Merck's Potential AIDS Breakthrough

Published in AIDS Weekly, February 14th, 2000

Scientists have become increasingly frustrated in the hunt for novel ways to attack the AIDS virus, but now they're getting some encouraging news: drug giant Merck & Co. has mapped the way toward a long-elusive target.

It will take years of additional research to turn the finding into a usable medication, experts cautioned. But the research gives scientists another - and long-awaited - place to aim at in fighting the HIV virus, important as today's AIDS drugs slowly lose their edge with few options in sight.

It's called integrase, an enzyme carried by the AIDS virus that causes a crucial step in HIV infection. It melds HIV's genetic material with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-02-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry